Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance
Marco Sanduzzi Zamparelli, Sergio Muñoz Martinez, Mariona Calvo, Marı́a Varela, Neus Llarch, Gemma Iserte, Berta Laquente, Andrés Castaño‐García, José Luis Lledó, Christie Perelló, Gemma Domènech, Ezequiel Mauro, Ángeles García‐Criado, Carmen Ayuso, Angels Kateb, Jordi Rimola, Jordi Bruix, María Reig
Journal of Hepatology, 2023
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
- High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma 2020
- Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma 2011
- Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance 2023
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma 2010
- [Advanced hepatocellular carcinoma: importance of clinical trials]. 2015